Third Harmonic Bio CSO Christopher Dinsmore steps down effective April 21, 2025

Third Harmonic Bio, Inc.

Christopher Dinsmore resigned as Chief Scientific Officer on April 21, 2025.
He will receive a lump-sum severance of 9 months' salary and healthcare cost coverage for up to 9 months.
Separation agreement includes release of claims, non-disparagement, and confidentiality provisions.
No successor has been announced; Dinsmore's departure leaves the CSO role vacant.
Severance benefits are contingent on compliance with the separation agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Dinsmore

Chief Scientific Officer

Third Harmonic Bio, Inc.

Effective: 2025-04-21
Filed: April 22, 2025, 7:59 PM ET

On April 21, 2025, Third Harmonic Bio, Inc. (the “ Company ”) and Christopher Dinsmore, Chief Scientific Officer of the Company, entered into a separation agreement with the Company (the “ Separation Agreement ”), pursuant to which Dr. Dinsmore would step down as Chief Scientific Officer effective April 21, 2025 (the “ Separation Date ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Dinsmore resigned as Chief Scientific Officer at Third Harmonic Bio, Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On April 21, 2025, Third Harmonic Bio, Inc. (the “ Company ”) and Christopher Dinsmore, Chief Scientific Officer of the Company, entered into a separation agreement with the Company (the “ Separation Agreement ”), pursuant to which Dr. Dinsmore would step down as Chief Scientific Officer effective April 21, 2025 (the “ Separation Date ”).

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-089270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.